Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Identifieur interne : 000E37 ( Main/Exploration ); précédent : 000E36; suivant : 000E38Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Auteurs : Golnasim Riahi ; Marc Morissette ; Pershia Samadi ; Martin Parent ; Thérèse Di PaoloSource :
- Biochemical pharmacology [ 1873-2968 ] ; 2013.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology), Animals, Autoradiography, Basal Ganglia (drug effects), Basal Ganglia (metabolism), Behavior, Animal (drug effects), Benzamides (metabolism), Brain (drug effects), Brain (metabolism), Case-Control Studies, Dyskinesia, Drug-Induced (metabolism), Dyskinesia, Drug-Induced (prevention & control), Levodopa (adverse effects), Macaca fascicularis, Parkinson Disease (metabolism), Pyridines (metabolism), Receptor, Serotonin, 5-HT1B (metabolism), Serotonin (metabolism), Sulfonamides (pharmacology), Thiazoles (pharmacology).
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , metabolism : Benzamides, Pyridines, Receptor, Serotonin, 5-HT1B, Serotonin.
- chemical , pharmacology : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Sulfonamides, Thiazoles.
- drug effects : Basal Ganglia, Behavior, Animal, Brain.
- metabolism : Basal Ganglia, Brain, Dyskinesia, Drug-Induced, Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- Animals, Autoradiography, Case-Control Studies, Macaca fascicularis.
Abstract
L-DOPA-induced dyskinesias (LID)s are abnormal involuntary movements limiting the chronic use of L-DOPA, the main pharmacological treatment of Parkinson's disease (PD). Serotonin receptors are thought to contribute to LID but serotonin 1B (5-HT1B) receptors have never been investigated in any primate models of PD and LID. Therefore, we measured 5-HT1B receptors with [(3)H]GR 125743 autoradiography in controls, MPTP-lesioned monkeys, and L-DOPA-treated MPTP monkeys, with or without Ro 61-8048 treatment, a kynurenine hydroxylase inhibitor alleviating LID. In normal condition, 5-HT1B receptor specific binding was highest in the substantia nigra pars reticulata (SNr), high in the globus pallidus (GP), nucleus accumbens and substantia innominata and lower in the caudate nucleus and putamen. 5-HT1B receptors were increased in caudate nucleus, putamen and SNr of MPTP monkeys compared to controls. L-DOPA-treated MPTP monkeys had elevated 5-HT1B receptor specific binding in caudate nucleus, putamen, SNr and internal GP. In all these brain regions, increases were prevented by co-administration of Ro 61-8048. No effect of MPTP lesion or treatment was observed for 5-HT1B specific binding in the external GP, nucleus accumbens and substantia innominata. This study is the first description in primates of altered brain 5-HT1B receptors associated with prevention of LID.
DOI: 10.1016/j.bcp.2013.08.005
PubMed: 23954709
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000853
- to stream PubMed, to step Curation: 000853
- to stream PubMed, to step Checkpoint: 000853
- to stream Ncbi, to step Merge: 001542
- to stream Ncbi, to step Curation: 001542
- to stream Ncbi, to step Checkpoint: 001542
- to stream Main, to step Merge: 000E49
- to stream Main, to step Curation: 000E37
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.</title><author><name sortKey="Riahi, Golnasim" sort="Riahi, Golnasim" uniqKey="Riahi G" first="Golnasim" last="Riahi">Golnasim Riahi</name><affiliation><nlm:affiliation>Faculty of Pharmacy, Université Laval, Quebec City, Canada, G1K 7P4; Neuroscience Research Unit, Centre de recherche du CHU de Québec, Quebec City, Canada, G1V 4G2; Centre de Recherche de l'Institut universitaire en santé mentale de Québec, Quebec City, Canada, G1J 2G3.</nlm:affiliation><wicri:noCountry code="subField">G1J 2G3</wicri:noCountry></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></author><author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name></author><author><name sortKey="Parent, Martin" sort="Parent, Martin" uniqKey="Parent M" first="Martin" last="Parent">Martin Parent</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23954709</idno><idno type="pmid">23954709</idno><idno type="doi">10.1016/j.bcp.2013.08.005</idno><idno type="wicri:Area/PubMed/Corpus">000853</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000853</idno><idno type="wicri:Area/PubMed/Curation">000853</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000853</idno><idno type="wicri:Area/PubMed/Checkpoint">000853</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000853</idno><idno type="wicri:Area/Ncbi/Merge">001542</idno><idno type="wicri:Area/Ncbi/Curation">001542</idno><idno type="wicri:Area/Ncbi/Checkpoint">001542</idno><idno type="wicri:Area/Main/Merge">000E49</idno><idno type="wicri:Area/Main/Curation">000E37</idno><idno type="wicri:Area/Main/Exploration">000E37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.</title><author><name sortKey="Riahi, Golnasim" sort="Riahi, Golnasim" uniqKey="Riahi G" first="Golnasim" last="Riahi">Golnasim Riahi</name><affiliation><nlm:affiliation>Faculty of Pharmacy, Université Laval, Quebec City, Canada, G1K 7P4; Neuroscience Research Unit, Centre de recherche du CHU de Québec, Quebec City, Canada, G1V 4G2; Centre de Recherche de l'Institut universitaire en santé mentale de Québec, Quebec City, Canada, G1J 2G3.</nlm:affiliation><wicri:noCountry code="subField">G1J 2G3</wicri:noCountry></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></author><author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name></author><author><name sortKey="Parent, Martin" sort="Parent, Martin" uniqKey="Parent M" first="Martin" last="Parent">Martin Parent</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></analytic><series><title level="j">Biochemical pharmacology</title><idno type="eISSN">1873-2968</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology)</term><term>Animals</term><term>Autoradiography</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia (metabolism)</term><term>Behavior, Animal (drug effects)</term><term>Benzamides (metabolism)</term><term>Brain (drug effects)</term><term>Brain (metabolism)</term><term>Case-Control Studies</term><term>Dyskinesia, Drug-Induced (metabolism)</term><term>Dyskinesia, Drug-Induced (prevention & control)</term><term>Levodopa (adverse effects)</term><term>Macaca fascicularis</term><term>Parkinson Disease (metabolism)</term><term>Pyridines (metabolism)</term><term>Receptor, Serotonin, 5-HT1B (metabolism)</term><term>Serotonin (metabolism)</term><term>Sulfonamides (pharmacology)</term><term>Thiazoles (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Benzamides</term><term>Pyridines</term><term>Receptor, Serotonin, 5-HT1B</term><term>Serotonin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Sulfonamides</term><term>Thiazoles</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Behavior, Animal</term><term>Brain</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term><term>Brain</term><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Autoradiography</term><term>Case-Control Studies</term><term>Macaca fascicularis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">L-DOPA-induced dyskinesias (LID)s are abnormal involuntary movements limiting the chronic use of L-DOPA, the main pharmacological treatment of Parkinson's disease (PD). Serotonin receptors are thought to contribute to LID but serotonin 1B (5-HT1B) receptors have never been investigated in any primate models of PD and LID. Therefore, we measured 5-HT1B receptors with [(3)H]GR 125743 autoradiography in controls, MPTP-lesioned monkeys, and L-DOPA-treated MPTP monkeys, with or without Ro 61-8048 treatment, a kynurenine hydroxylase inhibitor alleviating LID. In normal condition, 5-HT1B receptor specific binding was highest in the substantia nigra pars reticulata (SNr), high in the globus pallidus (GP), nucleus accumbens and substantia innominata and lower in the caudate nucleus and putamen. 5-HT1B receptors were increased in caudate nucleus, putamen and SNr of MPTP monkeys compared to controls. L-DOPA-treated MPTP monkeys had elevated 5-HT1B receptor specific binding in caudate nucleus, putamen, SNr and internal GP. In all these brain regions, increases were prevented by co-administration of Ro 61-8048. No effect of MPTP lesion or treatment was observed for 5-HT1B specific binding in the external GP, nucleus accumbens and substantia innominata. This study is the first description in primates of altered brain 5-HT1B receptors associated with prevention of LID.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name><name sortKey="Parent, Martin" sort="Parent, Martin" uniqKey="Parent M" first="Martin" last="Parent">Martin Parent</name><name sortKey="Riahi, Golnasim" sort="Riahi, Golnasim" uniqKey="Riahi G" first="Golnasim" last="Riahi">Golnasim Riahi</name><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23954709
|texte= Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23954709" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |